comparemela.com

Latest Breaking News On - Crispr therapeutics ag stock exchange - Page 1 : comparemela.com

CRISPR Therapeutics : Initiated clinical trials for next generation CAR T candidates, CTX112™ targeting CD19+ B-cell malignancies and CTX131™, targeting CD70+ solid tumors - Form 8-K

-Initiated clinical trials for next generation CAR T candidates, CTX112™ targeting CD19+ B-cell malignancies and CTX131™, targeting CD70+ solid tumors- -Enrollment. | May 8, 2023

United statesSan franciscoUnited kingdomCity ofBrad bolzonSusan kimRaju prasadSamarth kulkarniRachel eidesDrug administrationWilliam blair companySenior equity research analystViacyte incRegulatory agencyEuropean unionTherapeutics inc

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

-Regulatory submissions complete for exagamglogene autotemcel , formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia and severe sickle cell disease - -EU and U.K.. | May 8, 2023

United statesSan franciscoCity ofUnited kingdomSusan kimSamarth kulkarniRaju prasadBrad bolzonRachel eidesExchange commissionDrug administrationGlobenewswire incEuropean medicines agencyAmerican association for cancer researchRegulatory agencyViacyte inc

CRISPR Therapeutics : Regulation FD Presentation - Form 8-K

a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and. | April 3, 2023

United statesUnited kingdomSan franciscoCity ofRachel eidesSusie lisaCarmen bozicManisha paiMiroslava minkovaHeather nicholsPhuong khanhSusan kimTherapeutics incEuropean commissionVertex pharmaceuticals incorporatedExchange commission

CRISPR Therapeutics Announces Departure of Board Member

ZUG, Switzerland and BOSTON, March 29, 2023 CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that. | March 29, 2023

San franciscoUnited statesUnited kingdomCity ofRachel eidesRodger novakBrad bolzonSusan kimSamarth kulkarniGlobenewswire incViacyte incVertex pharmaceuticalsTherapeutics incManaging directorChief executive officerCrispr therapeutics ag stock exchange

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

ZUG, Switzerland and BOSTON, Sept. 28, 2022 CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that. | September 28, 2022

United statesUnited kingdomCity ofSan franciscoSusan kimRachel eidesPhuong khanhExchange commissionVertex pharmaceuticalsViacyte incTherapeutics incDrug administrationGlobenewswire incRegenerative medicine advanced therapyMycosis fungoidesChief medical officer

vimarsana © 2020. All Rights Reserved.